Core Points - Evommune, Inc. has priced its initial public offering (IPO) at $16.00 per share, offering 9,375,000 shares, with expected gross proceeds of $150 million [1][2] - The shares are set to begin trading on the New York Stock Exchange under the symbol "EVMN" on November 6, 2025, with the offering expected to close on November 7, 2025 [2] - The company is focused on developing innovative therapies targeting chronic inflammatory diseases, aiming to improve patients' daily lives and address the limitations of existing therapies [5] Company Overview - Evommune, Inc. is a clinical-stage biotechnology company dedicated to creating therapies that address key drivers of chronic inflammatory diseases [5] - The company's mission includes preventing long-term effects of uncontrolled inflammation through a portfolio of differentiated product candidates [5] Offering Details - The IPO includes a 30-day option for underwriters to purchase an additional 1,406,250 shares at the initial offering price [1] - Joint book-running managers for the offering include Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor [2]
Evommune Announces Pricing of its Initial Public Offering